Multivariate survival analysis was performed by using Coxs regression. The expression differences among target genes were analyzed using paired t test. P 0. 05 selleck screening library was con sidered to be statistically significant. Results E2F1 was highly expressed in SCLC Although expression of E2F1 had been detected in lung cancer tissue, its expression was inconsistent among different populations, especially in NSCLC. There fore, we firstly examined E2F1 levels in human lung cancer tissues in a Chinese Han population. E2F1 expression was positive in 95. 56% of SCLC, 50% of large lung cancer cell, and 10% of adenocarcin oma samples compared with the normal alveolar sections. However, it was not detected in squamous tissues. The normal bronchial epithelial tissues with exclusive E2F1 expression served as positive controls.

In 90 SCLC samples, the numbers of negative, weak, moder ate, and strong positive E2F1 staining cases were 4, 11, 23, and 52, respectively. In adenocarcinoma samples, only two weak positive staining cases were found. In LCLC samples, two weak and three strong positive staining cases were found. Consistent Inhibitors,Modulators,Libraries with these observations, E2F1 was positively expressed in H1688 and H446 cell lines as well as HBE cells, which served as the positive control. However, weak expressions were detected in A549, H1299 and H292 cell lines compared with SCLC cells. In addition, E2F1 was not detected in SK MES 1 and HFL 1 cell lines. Therefore, E2F1 expression was predominantly elevated in SCLC tissues and cell lines, suggesting the importance of E2F1 in SCLC development and progression.

E2F1 was an independent and adverse prognostic factor for SCLC patients E2F1 was highly expressed in SCLC, but not NSCLC. We next evaluated the association between Inhibitors,Modulators,Libraries E2F1 lower, moderate, Inhibitors,Modulators,Libraries and higher expression and clinicopathological variables by Spearmans analysis. The results in Table 5 showed that E2F1 was significantly associated with clinical stage. Samples from patients with lim ited disease displayed weakly Inhibitors,Modulators,Libraries expressed E2F1, whereas strong staining of E2F1 was found in patients with extensive disease. 2 test was performed to evaluate the significant difference between E2F lower, moderate and higher and clinicopathological variables, and the results showed that there was significant differ ence between E2F1 lower, moderate and higher and clin ical stage.

Patient survival time was collected by follow up and data showed that the median survival period of patients displaying lower E2F1 was 15. 67 months, and the moderate E2F1 and higher E2F1 expression groups were 13. 74, and 10. 21 months, re spectively. These results suggested that Inhibitors,Modulators,Libraries high level of E2F1 was correlated with poor survival in SCLC. More over, univariate survival analysis revealed that E2F1 and clinical stage were prognosis factors in SCLC patients, while other fac tors including Veliparib IC50 gender, age, smoking, tumor size were not significant.